Drug Profile
TP 0413
Alternative Names: TP-0413Latest Information Update: 21 Jul 2023
Price :
$50
*
At a glance
- Originator Tolero Pharmaceuticals
- Developer Sumitomo Pharma America
- Class
- Mechanism of Action Bone morphogenetic protein modulators; Hepcidin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma Oncology is now called Sumitomo Pharma Oncology
- 01 Jul 2020 Boston Biomedical has merged with Tolero Pharmaceuticals to form Sumitomo Dainippon Pharma Oncology
- 28 Sep 2018 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral)